Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse

BACKGROUND: Not enough evidence exists to compare buprenorphine–naloxone with extended-release naltrexone for treating opioid use disorder. OBJECTIVE: To evaluate the relative cost-effectiveness of buprenorphine–naloxone versus extended-release naltrexone. DESIGN: Cost-effectiveness analysis alongsi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Intern Med
Autors principals: Murphy, Sean M., McCollister, Kathryn E., Leff, Jared A., Yang, Xuan, Jeng, Philip J., Lee, Joshua D., Nunes, Edward V., Novo, Patricia, Rotrosen, John, Schackman, Bruce R.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6581635/
https://ncbi.nlm.nih.gov/pubmed/30557443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M18-0227
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars